Dossier assessment
Ramucirumab - Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Ramucirumab - Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Ramucirumab - Benefit assessment according to §35a Social Code Book V
Press releases
Ramucirumab in stomach cancer: added benefit not proven
Former orphan drug is undergoing regular early benefit assessment / studies submitted were unsuitable
Project details
- Project no.
- A16-23
- Commission
- Commission awarded on 29.04.2016 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Dossier assessment
Ramucirumab (NSCLC, combination with erlotinib) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Ramucirumab (hepatocellular carcinoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Ramucirumab (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Ramucirumab (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Ramucirumab - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment)
Status: Commission completed